| Li, Jing |
NCT04624854: Dual Anti-Platelet Therapy in Patients With Coronary Multi-Vessel Disease (DAPT-MVD) |
|
|
| Active, not recruiting | 4 | 8250 | RoW | Clopidogrel and Aspirin dual-antiplatelet therapy, Aspirin monotherapy | Harbin Medical University, Chinese Society of Cardiology, Lepu Medical Technology (Beijing) Co., Ltd. | Coronary Artery Disease, Myocardial Ischemia, Acute Coronary Syndrome, Heart Diseases, Syndrome Heart Disease, Cardiovascular Diseases, Arteriosclerosis, Arterial Occlusive Diseases, Coronary Disease, Vascular Diseases | 04/25 | 04/25 | | |
| Terminated | 3 | 372 | Europe, US, RoW | Pamrevlumab, FG-3019, Placebo | FibroGen | Idiopathic Pulmonary Fibrosis | 09/23 | 09/23 | | |
|
| Active, not recruiting | 3 | 404 | Europe, Canada, Japan, US, RoW | Atrasentan, CHK-01, Atrasentan Hydrochloride, ABT-627, Placebo | Chinook Therapeutics, Inc. | IgA Nephropathy, Immunoglobulin A Nephropathy | 12/26 | 12/26 | | |
NCT06206278: Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ Adenocarcinoma |
|
|
| Terminated | 2 | 6 | RoW | Infigratinib, BGJ398, BBP-831 | LianBio LLC | Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | 05/24 | 05/24 | | |
| Not yet recruiting | 2 | 120 | RoW | Metformin Hydrochloride tablet, Metformin, Placebo | Xuanwu Hospital, Beijing, Institute of Zoology, Chinese Academy of Sciences, Beijing Institute of Genomics, Chinese Academy of Sciences, Merck Serono Co., Ltd., China | Metformin, Aging | 09/26 | 07/28 | | |
NCT05593575: Efficacy and Safety of SPH3127 Tablets on Treating the Diabetic Kidney Disease |
|
|
| Recruiting | 2 | 320 | RoW | SPH3127+SPH3127matching placebo+valsartan matching placebo, SPH3127+valsartan matching placebo, SPH3127 matching placebo+valsartan | Shanghai Pharmaceuticals Holding Co., Ltd | Diabetic Kidney Disease | 06/25 | 06/25 | | |
FRUSICA-1, NCT03903705: : A Phase Ib/II Study To Evaluate Fruquintinib Monotherapy Or Plus Sintilimab In Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 381 | RoW | Fruquintinib in Combination with Sintilimab, Fruquintinib | Hutchmed | Advanced Solid Tumor | 12/25 | 12/25 | | |
| Recruiting | N/A | 100 | RoW | Automated peritoneal dialysis, Intermittent hemodialysis | Limeng Chen, First Hospital of China Medical University, First Affiliated Hospital Xi'an Jiaotong University, Beijing Anzhen Hospital, Xiangya Hospital of Central South University, Baxter Healthcare Corporation | Acute Kidney Injury | 12/22 | 12/22 | | |
NCT06025045: Dynamic Monitoring of ctDNA Predicts Recurrence of Advanced Ovarian Cancer After Primary Treatments |
|
|
| Recruiting | N/A | 50 | RoW | | Jing Li, Nanjing Shihejiyin Technology, Inc. | Ovarian Cancer Stage IV, Ovarian Cancer Stage III | 08/25 | 08/25 | | |
| Friedman, David |
BRUIN CLL-321, NCT04666038: Study of LOXO-305 Versus Investigator's Choice (IdelaR or BR) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) |
|
|
| Active, not recruiting | 3 | 250 | Europe, Canada, Japan, US, RoW | LOXO-305, Pirtobrutinib, Idelalisib, Zydelig, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima | Loxo Oncology, Inc., Eli Lilly and Company | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 08/23 | 05/27 | | |
BRUIN CLL-322, NCT04965493 / 2021-000043-49: A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) |
|
|
| Recruiting | 3 | 600 | Europe, Canada, Japan, US, RoW | Pirtobrutinib, LOXO-305, LY3527727, Venetoclax, Venclexta, Venclyxto, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience | Loxo Oncology, Inc., Eli Lilly and Company | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 04/26 | 01/27 | | |
| Chen, Chao Wen |
NCT05352516 / 2022-002188-31: A Study to Evaluate the Efficacy and Safety of HLX14 vs. Denosumab Prolia® in Postmenopausal Women With Osteoporosis at High Risk of Fracture |
|
|
| Completed | 3 | 514 | RoW | HLX14, Prolia® | Shanghai Henlius Biotech, Shanghai Henlius Biotech, Inc. | Postmenopausal | 12/23 | 07/24 | | |
| Yang, Xiao Dong |
NCT05721404: Icodextrin Postpones the Shift of Low Dose to Full Dose Dialysis in the First Year of Incremental Peritoneal Dialysis |
|
|
| Recruiting | 4 | 194 | RoW | Icodextrin Peritoneal Dialysis Solution, Hypertonic Dextrose solution | First Affiliated Hospital, Sun Yat-Sen University, Baxter Healthcare Corporation | Peritoneal Dialysis | 04/25 | 12/25 | | |
| Active, not recruiting | N/A | 195 | RoW | Novel spectacle lens design, Spectacle lenses | SightGlass Vision, Inc. | Juvenile Myopia, Myopia | 09/25 | 03/26 | | |
| Congdon, Nathan |
| Completed | N/A | 993 | RoW | Results utilized from autonomous AI diagnostic system for diabetic retinopathy and/or diabetic macular edema | Orbis, Digital Diagnostics, Inc., Deep Eye Care Foundation (DECF) | Diabetic Retinopathy, Diabetic Macular Edema | 07/22 | 07/22 | | |
| Wang, Ningli |
| Active, not recruiting | 3 | 777 | RoW | Lower dose atropine sulfate eye drops, Lower dose atropine sulfate, Low dose atropine sulfate eye drops, Low dose atropine sulfate, placebo, Vehicle | Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. | Myopia | 03/25 | 08/25 | | |
NCT06465537: CRISPR/Cas9 Instantaneous Gene Editing Therapy to Intraocular Hypertensive POAG With MYOC Mutation |
|
|
| Recruiting | N/A | 9 | RoW | BD113vVLP, BD113 virus-like particle, CRISPR/Cas9 mRNA instantaneous gene editing technology | Shanghai BDgene Co., Ltd., Beijing Tongren Hospital | Primary Open Angle Glaucoma | 12/25 | 12/25 | | |
| Lu, Lin |
BL0006-101, NCT06247657: A Phase I Study to Assess the Safety and Tolerability of BL0006 for Patients With Advanced Solid Tumours |
|
|
| Recruiting | 1 | 66 | RoW | BL0006 | Shanghai Best-Link Bioscience, LLC | Advanced Solid Tumor | 10/24 | 05/25 | | |
| Yang, Hui |
| Active, not recruiting | 3 | 291 | Europe, Canada, Japan, US, RoW | Selpercatinib, LY3527723, LOXO-292, Cabozantinib, Vandetanib | Loxo Oncology, Inc., Eli Lilly and Company | Medullary Thyroid Cancer | 05/23 | 02/26 | | |
NCT05042375: A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer |
|
|
| Recruiting | 3 | 450 | RoW | camrelizumab + famitinib, pembrolizumab, camrelizumab | Jiangsu HengRui Medicine Co., Ltd. | Non-small Cell Lung Cancer | 12/23 | 12/25 | | |
nAMD, NCT05461339: TAB014 Compared to Lucentis® in Patients with Neovascular Age-related Macular Degeneration |
|
|
| Active, not recruiting | 3 | 488 | RoW | TAB014 Monoclonal Antibody Injection, TAB014, Ranibizumab Injection [Lucentis], Lucentis | TOT Biopharm Co., Ltd., Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. | Neovascular Age-related Macular Degeneration | 09/24 | 02/25 | | |
NCT05837897: A Study of Vedolizumab in Adult Participants With Moderate to Severe Crohn's Disease |
|
|
| Recruiting | 3 | 408 | RoW | Vedolizumab IV, Placebo | Takeda | Crohn's Disease | 03/30 | 05/31 | | |
NCT05486104: Phase II Study of Hemay005 in Patients With Active Ulcerative Colitis |
|
|
| Recruiting | 2 | 108 | RoW | Hemay005 tablets, Hemay005 45 mg BID group, Hemay005 placebo tablets, Hemay005 placebo BID group | Ganzhou Hemay Pharmaceutical Co., Ltd | Moderate to Severe Ulcerative Colitis | 06/24 | 09/24 | | |
TQC3721-II-03, NCT06527144: A Clinical Trial of TQC3721 Suspension for Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease |
|
|
| Recruiting | 2 | 240 | RoW | 3mg TQC3721 Suspension for Inhalation, 6mg TQC3721 Suspension for Inhalation, Placebo TQC3721 suspension for inhalation | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Pulmonary Disease, Chronic Obstructive | 02/25 | 12/25 | | |
NCT06310590: Safety and Efficacy of NRT6003 in Patients With Unresectable Hepatocellular Carcinoma |
|
|
| Recruiting | 1 | 40 | RoW | NRT6003 Injection, Yttrium-90 carbon microspheres | Chengdu New Radiomedicine Technology Co. LTD. | Unresectable Hepatocellular Carcinoma | 10/25 | 10/25 | | |
| chen, xiang |
nAMD, NCT05461339: TAB014 Compared to Lucentis® in Patients with Neovascular Age-related Macular Degeneration |
|
|
| Active, not recruiting | 3 | 488 | RoW | TAB014 Monoclonal Antibody Injection, TAB014, Ranibizumab Injection [Lucentis], Lucentis | TOT Biopharm Co., Ltd., Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. | Neovascular Age-related Macular Degeneration | 09/24 | 02/25 | | |
NCT05181137 / 2021-001940-86: A Phase 3 Study to Investigate the Efficacy and Safety of SHR0302 With Moderately to Severely Active Ulcerative Colitis |
|
|
| Recruiting | 3 | 368 | Europe, US, RoW | SHR0302, Placebo | Reistone Biopharma Company Limited, Reistone Biopharma Company Limited | Ulcerative Colitis | 10/24 | 03/25 | | |
NCT06365502: Preventive Drug-coated Balloon Angioplasty in Vulnerable Atherosclerotic Plaque (RESTORE Trial) |
|
|
| Recruiting | N/A | 1860 | RoW | Drug-coated balloon, Guideline-directed medical treatment | Harbin Medical University, Shanghai Shenqi Medical Technology Co., Ltd | Acute Coronary Syndrome (ACS) | 12/27 | 12/30 | | |
| Ma, Jin |
VOC, NCT04827368: Volatile Organic Compounds (s) in Active Inflammatory Bowel Disease |
|
|
| Recruiting | N/A | 300 | US | Breath Test, Serum Samples, Stool Samples | The Cleveland Clinic, AbbVie | IBD, Crohn Disease, Ulcerative Colitis | 04/25 | 09/25 | | |
| Lin, Mingkai |
NCT05130554: XEN45 in the Treatment of Chinese Patients With Primary Open-angle Glaucoma |
|
|
| Active, not recruiting | N/A | 20 | RoW | XEN45 gel stent implantation, XEN | Zhongshan Ophthalmic Center, Sun Yat-sen University, Allergan | Glaucoma, Glaucoma, Open-Angle, Surgery | 06/22 | 09/22 | | |
| Liu, Zhenzhen |
NCT06254742: A Trial of HHPG-19K Injection and Auto-HHPG-19K Injection in Prevention of Chemotherapy-related Moderate to Severe Neutropenia of Patients With Nonmyeloid Malignancies |
|
|
| Not yet recruiting | 3 | 107 | RoW | HHPG-19K Injection | Jiangsu HengRui Medicine Co., Ltd. | Patients With Nonmyeloid Malignancies Receiving Antineoplastic Therapy Based on Chemotherapy Regimens at Moderate to High Febrile Neutropenia (FN) Risk | 05/24 | 06/24 | | |
NCT05253053: To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 114 | RoW | TT-00420, Combination Product: Atezolizumab, Combination Product: Nab-Paclitaxel | TransThera Sciences (Nanjing), Inc. | Advanced Solid Tumor, Cholangiocarcinoma, Biliary Tract Cancer, HER2-negative Breast Cancer, Triple Negative Breast Cancer, Small-cell Lung Cancer, Bladder Cancer, Prostate Cancer, Thyroid Cancer, Gastric Cancer, Gallbladder Cancer | 09/24 | 12/24 | | |
| chen, shida |
| No trials found |
| Dai, Ye |
| No trials found |
| Wang, Jinghui |
| No trials found |
| Liu, Xialin |
| No trials found |
| Zhou, Tian |
| No trials found |
| Zhang, Qingjiong |
| No trials found |
| Lin, Haowen Lin Haowen |
| No trials found |
| Yang, Ziqi |
| No trials found |
| Li, Jinrong |
| No trials found |
| Chi, Wei |
| No trials found |
| Gao, Xinbo |
| No trials found |
